Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Investor Presentation (January 2023)
41 slides from Day One Biopharmaceuticals's investor presentation, Jan 9, 2023
Slide 1: Targeted Therapies for People of All Ages
Exhibit 99.2 Day One Biopharmaceuticals Targeted Therapies for People of All Ages January 2023 Day One Biopharmaceuticals 1
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some
Slide 3: Cancer Drug Development for People of All Ages
Cancer Drug Development for People of All Ages Mission That Tovorafenib (DAY101) Growing Portfolio and Runway Creates Value Lead Program Beyond Clinical Milestones • Day One’s mission is to help children • Investigational, oral, CNS-penetrant • Two clinical-stage MEKi assets, in- with cancer, from d
Slide 4: A Senior Team with Deep Experience in Pediatric and Adult Oncology
A Senior Team with Deep Experience Developing and Commercializing Products in Pediatric and Adult Oncology Markets Jeremy Bender, PhD, MBA Samuel Blackman, MD, PhD Charles York II, MBA Chief Executive Officer Chief Medical Officer & Founder Chief Operating and Financial Officer VP of Corporate Devel
Slide 5: Our Pipeline
Our Pipeline Recent & Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Topline data presented: January 2023 Pre-NDA meeting & NDA 1 Relapsed pLGG FIREFLY-1 (pivotal) submission planned: 1H 2023 Tovorafenib (DAY101) NDA data set presentation Type II Pan-RAF Inhi
Slide 6: Tovorafenib (DAY101) Type II Pan-RAF Inhibitor
Tovorafenib (DAY101) Type II Pan-RAF Inhibitor Day One Biopharmaceuticals 6
Slide 7: Pediatric Low-Grade Gliomas (pLGG)
Pediatric Low-Grade Gliomas (pLGG) • Despite being the most common brain tumor in children, there are no approved agents and no standard-of-care for the majority of patients 1,2 with relapsed/progressive disease ‒ ~70% of patients will require systemic therapy ‒ Patients have a high rate of recurren
Slide 8: Tovorafenib (DAY101) Inhibits Both BRAF Fusions and BRAF V600 Mutations
Tovorafenib (DAY101) Inhibits Both BRAF Fusions and BRAF V600 Mutations • Tovorafenib (DAY101) is an investigational, MAPK pathway RAS-independent activation of the MAPK pathway oral, selective, CNS-penetrant, type II pan- RAF inhibitor that was designed to inhibit RAS both monomeric and dimeric RAF
Slide 9: The Current pLGG Treatment Paradigm
The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor Presentation Surgical Intervention 1L 2L 3L ~35% 20% Targeted Tx Targeted Tx Targeted Tx GTR No Recurrence (5-10%) (40-50%) (40-50%) 1 Biopsy (>95%) Suspected ~65% ~50% ~50% pLGG ≤ Partial Eventual Additi
Slide 10: Pivotal Phase 2 Trial of Tovorafenib in Relapsed or Progressive pLGG (FIREFLY-1)
Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) in Relapsed or Progressive pLGG (FIREFLY-1) Trial Design Endpoints (Pivotal Arm 1) • Three arm, open-label, global registrational phase 2 trial • Primary endpoint: ORR based on RANO criteria, assessed by blinded independent central review • P
Slide 11: FIREFLY-1 Baseline Patient Characteristics
FIREFLY-1 Baseline Patient Characteristics Location (n=77) Cerebral hemisphere Deep midline structures 8% 12% Topline Data Characteristic Arm 1 (N=77) Other 16% Median age, years (range) 8 (2-21) BRAF alteration, n (%) Optic pathway Cerebellum 51% BRAF V600E 13 (17) 6% † BRAF Fusion 64 (83) Brain st
Slide 12: Topline Data from Ongoing Pivotal Phase 2 FIREFLY-1 Trial
Topline Data from Ongoing Pivotal Phase 2 FIREFLY-1 Trial The primary endpoint of the FIREFLY-1 trial is overall response rate (ORR) by Response Assessment for Neuro-Oncology (RANO) criteria as assessed by blinded independent central review. In the 69 RANO-evaluable patients: • 64% ORR and 91% clini
Slide 13: Incidence and Prevalence of BRAF-altered pLGG in the U.S.
Incidence and Prevalence of BRAF-altered pLGG in the U.S. 2020 2017 Estimated Incidence Estimated SEER Prevalence Under 25 Under 25 1 US Population ~105,000,000 NA 2 3 Rate of CNS Tumors (0.00521%) ~5,500 ~130,000 2 Gliomas (63%) ~3,500 ~82,000 2 Low Grade (77%) ~2,600 ~63,000 2 Has Received Drug Tx
Slide 14: FIREFLY-2/LOGGIC Pivotal Phase 3 Trial in Newly Diagnosed pLGG
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Newly Diagnosed pLGG Day One Biopharmaceuticals 14
Slide 15: FIREFLY-2/LOGGIC Trial Design and Endpoints
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Newly Diagnosed pLGG Trial Design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RANO criteria, assessed by (DAY101) vs SoC chemotherapy blinded independent cen
Slide 16: FIREFLY-2/LOGGIC: Collaboration and Study Sites
FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG • Collaboration between Day One and the LOGGIC consortium, internationally recognized experts in pLGG research ‒ Coupled with the LOGGIC-CORE molecular diagnostic program ‒ Worked jointly on the study design and
Slide 17: Our Pipeline
Our Pipeline Recent & Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Topline data presented: January 2023 Pre-NDA meeting & NDA 1 Relapsed pLGG FIREFLY-1 (pivotal) submission planned: 1H 2023 Tovorafenib (DAY101) NDA data set presentation Type II Pan-RAF Inhi
Slide 18: Next-generation RAF Inhibitors Address Adult Cancers with RAF Wild-type Fusions
Next-generation RAF Inhibitors are Unique in Their Ability to Address Adult Cancers Associated with RAF Wild-type Fusions Tovorafenib (DAY101) has demonstrated monotherapy BRAFwt fusion mixed Mullerian clinical activity in KIAA1549:BRAF and SRGAP3:CRAF wild- cancer type fusions in pLGG Activity of B
Slide 19: Phase 1b/2a Study of Monotherapy Tovorafenib in Solid Tumors (FIRELIGHT-1)
Phase 2 Study of Monotherapy Tovorafenib (DAY101) in Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints • Single arm, open-label, global phase 1b/2a trial • Primary endpoint: ORR by RECIST version 1.1 for non-CNS solid tumors and RANO criteria for any CNS tumors • n = 40 patients (approximately) •
Slide 20: Activity of Tovorafenib in SNX8:BRAF Fusion Spindle Cell Sarcoma
Activity of Tovorafenib (DAY101) in SNX8:BRAF Fusion Spindle Cell Sarcoma A male child spindle cell sarcoma, 5-years of age at diagnosis Months -30 -24 -18 -12 -6 0 6 CR PD CR Diagnosis Targeted Therapy BRAF fusion (FISH) Ifosfamide, doxorubicin, Tovorafenib Tovorafenib Subtotal resection dexrazoxan
Slide 21: Scientific Rationale for Combining Tovorafenib with Additional MAPK Pathway Inhibitors
Strong Scientific Rationale for Combining Tovorafenib (DAY101) with Additional MAPK Pathway Inhibitors BRAF or CRAF BRAF KRAS or NRAS NF1 non-V600 mutant LOF WT fusion MEK MEK RAF/ PI3K/m RAS/RAF/ME PI3K/ Signaling RAL MEK/ERK TOR K/ERK mTOR pathways ERK ERK Proliferation, survival Proliferation, su
Slide 22: Pimasertib MEK1/2 Inhibitor
Pimasertib MEK1/2 Inhibitor Day One Biopharmaceuticals 22
Slide 23: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor
Pimasertib: Investigational Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors RTKS GF • Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 GTP Cellular membrane • Extensive no
Slide 24: Vertical MAPK Pathway Inhibition with Tovorafenib and Pimasertib
Vertical MAPK Pathway Inhibition with Tovorafenib (DAY101) and Pimasertib May Unlock Potential Synergy for Adult Solid Tumors A B • The MAPK pathway normally has multiple feedback loops that negatively regulate upstream (RAS/RAF) activation to ensure optimal signaling • Monotherapy MEK inhibition di
Slide 25: Tovorafenib / Pimasertib Combination in Solid Tumors (FIRELIGHT-1)
Tovorafenib (DAY101) / Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints 2 • Combination dose escalation, global phase 1b/2 trial • Phase 1b: PK, PD and Safety, MTD/RP2D • Phase 1b, BOIN (adaptive), n = 10/cohort (approximately) • Phase 2: Efficacy (ORR, D
Slide 26: Summary
Summary Day One Biopharmaceuticals 26
Slide 27: Financial Summary: DAWN
Financial Summary: DAWN Cash, cash equivalents and short-term investments as of 73.5 million shares of common stock September 30, 2022: $374.3 million (no debt) outstanding as of November 2, 2022 Nine Months Ended Nine Months Ended $ Millions 9/30/22 9/30/21 R&D Expense $59.6 $32.4 G&A Expense $44.6
Slide 28: Next Steps
Next Steps FIREFLY-1 • Present NDA data set at medical meeting in Q2 2023 • Pre-NDA meeting and NDA submission planned for 1H 2023 FIREFLY-2 Topline data from pivotal Phase 2 FIREFLY-1 trial • Advance tovorafenib as a front-line therapy for patients newly diagnosed with demonstrating meaningful resp
Slide 29: Appendix
Appendix Day One Biopharmaceuticals 29
Slide 30: FIREFLY-1 Baseline Characteristics
FIREFLY-1 Baseline Characteristics Location (n=25) Characteristic Arm 1 (N=25) Deep midline structures Hypothalamus 12% Median age, years (range) 8 (3-18) 8% Sex, n (%) Other Male 13 (52) 16% Female 12 (48) Race, n (%) Optic pathway Cerebellum Black or African American 1 (4) 52% 4% Asian 2 (8) Brain
Slide 31: Tumor Response to Tovorafenib for RANO-Evaluable Patients
Tumor Response To Tovorafenib (DAY101) For All Patients With RANO- Evaluable Lesions (n=22)* RANO Evaluable Response (IRC) N=22* ORR (95% CI) 64% (41-83) BRAF fusion (n=20) 60% BRAF V600E (n=2) 100% # CBR 91% Best overall response PR (13/22) 59% uPR (1/22) 5% SD (6/22) 27% Apr 14, 2022 data cutoff.
Slide 32: Duration of Tovorafenib Therapy for RANO-Evaluable Patients
Duration of Tovorafenib (DAY101) Therapy For All Patients with RANO- Evaluable Lesions (n=22) 17/22 patients remain on therapy All responders remain on treatment Day One Biopharmaceuticals 32 Apr 14, 2022 data cutoff.
Slide 33: Individual Patient Tumor Change From Baseline
Individual Patient Tumor Change From Baseline (n=22 RANO-Evaluable By Blinded Independent Central Review) PD SD PR CR Apr 14, 2022 data cutoff. RANO PD = ≥+25% change from baseline; RANO SD = <+24% Months to > -50% change from baseline; RANO PR = ≤ -50% change from baseline; RANO CR = Day One Biopha
Slide 34: Tovorafenib Safety Data for the First Enrolled Patients
Tovorafenib (DAY101) Safety Data For the First 25 Enrolled Patients (TEAEs ≥25% Any Grade) Treatment-emergent AEs Treatment-related AEs Preferred term, n (%) Any grade Grade ≥3 Any grade Grade ≥3 • Most treatment-emergent AEs were Blood creatine phosphokinase increased 20 (80) 2 (8) 18 (72) 2 (8) gr
Slide 35: Key Takeaways
Key Takeaways • Encouraging initial efficacy data from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusion or BRAF V600 mutation, for whom there is no standard-of-care and no approved agents for the majority of patients ‒ 64% ORR and 91% clinical benefit rate (pa
Slide 36: Case Study: Tovorafenib in KIAA1549-BRAF Fusion Optic Pathway Glioma
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis Months -36 -30 -24 -18 -12 -6 0 6 PR 1L: Vincristine/carboplatin Dia
Slide 37: Case Study: Tovorafenib in Posterior Fossa Pilocytic Astrocytoma
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation Months -84 -72 -60 -48 -36 -24 -12 0 12 PR Suboccipital 2L: Carboplatin/vincristine 4L:
Slide 38: Case Study: Tovorafenib in BRAF V600E Deep Midline Astrocytoma
Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty -60 -48 -36 -24 -12 0 Months 12 PR Subtotal 1L: Carboplatin/vincristine 2L: Dabrafenib 3L: Tovorafenib resect
Slide 39: Results from Independent Radiology Review of PNOC014
Results from Independent Radiology Review of PNOC014 Best response from baseline RANO: Response assessment for neuro- oncology (FDA standard) Volumetric image analysis (exploratory) RAPNO: Response assessment for pediatric neuro-oncology (exploratory) Date of data cutoff: 02 JAN 2020 Day One Biophar
Slide 40: Rapid, Deep and Durable Responses in PNOC014
Multiple Rapid, Deep and Durable Responses Observed following Initiation of Tovorafenib (DAY101) Treatment of pLGG Patients in PNOC014 Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Day One Biopharmaceuticals 40 Fangusaro J et al. Lancet Oncol 20
Slide 41: Drug-related Adverse Events for Tovorafenib in PNOC014
Drug-related Adverse Events Observed for Tovorafenib (DAY101) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Drug-related AEs for Tovorafenib (DAY101) Drug-related AEs for selumetinib Toxicities Grade 1-2 Grade 3 Grade 4 Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Increa
Day One Biopharmaceuticals — Investor Presentation (January 2023) on 6ix